DMC Group LLC Sells 4,554 Shares of Moderna, Inc. (NASDAQ:MRNA)

DMC Group LLC decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 48.4% during the third quarter, HoldingsChannel.com reports. The fund owned 4,859 shares of the company’s stock after selling 4,554 shares during the quarter. DMC Group LLC’s holdings in Moderna were worth $325,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Fisher Asset Management LLC purchased a new stake in Moderna during the fourth quarter valued at $206,000. Los Angeles Capital Management LLC purchased a new stake in shares of Moderna during the 1st quarter valued at about $2,693,000. Mather Group LLC. bought a new position in shares of Moderna in the 1st quarter valued at about $57,000. Massmutual Trust Co. FSB ADV grew its position in Moderna by 71.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 571 shares of the company’s stock worth $61,000 after acquiring an additional 237 shares in the last quarter. Finally, Wedmont Private Capital bought a new stake in Moderna during the first quarter worth approximately $231,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Down 1.3 %

NASDAQ:MRNA opened at $54.10 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The firm has a market cap of $20.73 billion, a PE ratio of -3.45 and a beta of 1.66. The company has a 50-day moving average of $70.75 and a 200 day moving average of $104.57. Moderna, Inc. has a 1-year low of $53.55 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company’s quarterly revenue was down 29.9% on a year-over-year basis. During the same period last year, the firm earned ($3.62) earnings per share. As a group, research analysts anticipate that Moderna, Inc. will post -9.85 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the sale, the director now owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,184 shares of company stock valued at $3,804,931 over the last quarter. 15.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group lowered their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Sanford C. Bernstein began coverage on shares of Moderna in a research report on Thursday. They set a “market perform” rating and a $55.00 price objective on the stock. Piper Sandler lowered their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $97.18.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.